Posted on 11/6/17
Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and nine months ended September 30, 2017.Third Quarter 2017 Financial Highlights Total revenues . . .
Posted on 11/6/17
AmerisourceBergen Corporation 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by AmerisourceBergen Corporation in conjunction with their 2017 Q4 earnings call. 117READ FULL ARTICLE HERE
Posted on 11/6/17
Teva Punished After Weak Outlook
Teva CEO Kare SchultzTeva (TEVA) reported Q3 revenue of $5.61 billion and eps of $1.00. The company missed on revenue by $10 million and missed on . . .
Posted on 11/6/17
Teva: Value Trap
Investment ThesisI was previously bullish Teva (TEVA) while not being a shareholder. Now, I'm totally bearish but ended up being a shareholder. Which is ironic. Teva's . . .
Posted on 11/6/17
Merck: A Slow And Steady Dividend Grower, But Do Better Alternatives Exist?
Blue chip drug makers such as Merck (NYSE:MRK) have historically been very popular with income investors because of their defensive nature, meaning that drug demand isn't . . .
Posted on 11/6/17
3 Reasons It's Smart to Buy Celgene's Stock Now
Celgene Corp. (NASDAQ:CELG) shares nose-dived in October following a trial failure and third-quarter financials that failed to impress. However, there are good reasons investors ought to . . .
Posted on 11/6/17
Why Celgene Crashed 30% in October -- and What Now?
What happenedFew industry watchers expected much out of GED-0301, yet its failure in a phase 3 study, plus anemic sales growth for one of its most . . .
Posted on 12/5/17
Interview with Mike Daley, CEO of OrthogenRx - Part III
Brought to you by Newmark Knight Frank
Posted on 11/30/17
Interview with Mike Daley, CEO of OrthogenRx - Part II
Brought to you by Newmark Knight Frank
Posted on 11/27/17
Interview with Mike Daley, CEO of OrthogenRx - Part I
Brought to you by Newmark Knight Frank
Posted on 11/6/17
ADMA Biologics Provides Corporate Update
RAMSEY, N.J., Nov. 03, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that develops, manufactures and markets . . .
Posted on 11/6/17
Onconova Therapeutics to Provide Corporate Update
NEWTOWN, Pa., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat . . .
Posted on 11/6/17
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MALVERN, Pa., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies . . .
Posted on 11/3/17
5 Things Pfizer's Management Just Said That You Don't Want to Miss
Forget Pfizer's (NYSE:PFE) third-quarter earnings announcement. The real story lies in what the company's top executives said afterward.The big pharma company reported its third-quarter results on . . .
Posted on 11/3/17
Teva's Q3 And Crash: A Bear Reviews And Updates The Story
IntroductionAn explanation of why I write bearish articles on a number of companies is in order. I am a long-only investor. That may change if I . . .
Posted on 11/3/17
The Single Biggest Reason Teva Pharmaceutical Industries Imploded and Fell 22% in October
What happenedShares of Teva Pharmaceutical Industries (NYSE:TEVA), a developer of branded and generic drugs and the largest generic drugmaker in the world, tumbled another 22% in . . .
Posted on 11/2/17
Johnson & Johnson (JNJ) Quarterly Report
Posted on 11/2/17
Johnson & Johnson: Not Overvalued Per FCF Standpoint
With the level of growth that Johnson & Johnson (JNJ) has been witnessing this year, it's coming to be one of the last companies you would . . .
Posted on 11/2/17
Celgene's Gilead Moment
A 20% price drop on a single day following an earnings release, and a 30% loss in just five trading days is an unusual event for . . .
Posted on 11/2/17
Will Weak Guidance Sink Teva?
Copaxone. Source: Seeking AlphaTeva (TEVA) reports Q3 earnings Thursday. Analysts expect revenue of $5.62 billion and EPS of $1.04. The revenue estimate implies a 1% decline . . .
Posted on 11/2/17
Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Pfizer Inc. (NYSE:PFE)Q3 2017 Earnings Conference CallOct. 31, 2017, 8:00 a.m. EDTContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood day, everyone, and welcome to . . .
Posted on 11/2/17
Celgene Prices $3 Billion of Senior Unsecured Notes
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $3,000 million. Of . . .
Posted on 11/1/17
Merck's Keytruda Just Suffered A Large Setback
Merck (NYSE: MRK) reported third-quarter results last Friday. Results were generally mixed, with the stock down 8%. Financial results were adequate, with some lingering negative effects . . .
Posted on 11/1/17
Pfizer Inc. Q3 Earnings: The Most Important Things to Know
Pfizer's (NYSE:PFE) overall story so far in 2017 has been a mediocre one. The big pharma company's stock is up year to date, but barely half . . .

